[{"orgOrder":0,"company":"TheracosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TheracosBio Announces FDA Approval of Brenzavvy\u2122 (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TheracosBio Announces Commercial Availability of Brenzavvy (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"TheracosBio","sponsor":"SmithRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy\u2122 (bexagliflozin) to Members with Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Independent Pharmacy Cooperative","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY\u00ae (bexagliflozin) with TheracosBio Partnership","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by TheracosBio
Under the agreement, IPC gains distribution rights for Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, used for the treatment of adults with type 2 diabetes mellitus.
Under the collaboration, SmithRx will offer access to Brenzavvy (bexagliflozin), a sodium glucose transporter 2 (SGLT2) inhibitor and TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes.
Brenzavvy (bexagliflozin), a SGLT2 inhibitor which helps in reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Brenzavvy™ (bexagliflozin) is a SGLT2 inhibitor thus, reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.